Mayo Clinic’s Dr. Paul Limburg to join Exact Sciences medical leadership

Dr. Limburg is a gastroenterologist and a professor of medicine at Mayo Clinic. He is also a co-leader of the Cancer Prevention and Control program within Mayo Clinic Cancer Center.

MADISON, Wis., March 6, 2018 /PRNewswire/ -- EXACT Sciences Corporation (Nasdaq: EXAS) today announced that Paul J. Limburg, M.D., M.P.H., has been appointed the company’s co-chief medical officer. Dr. Limburg is a gastroenterologist and a professor of medicine at Mayo Clinic. He is also a co-leader of the Cancer Prevention and Control program within Mayo Clinic Cancer Center.

“We are delighted to welcome Dr. Limburg and believe he’ll play a critical leadership role in our mission to eradicate colon cancer,” said Kevin T. Conroy, chairman and CEO of Exact Sciences. “Dr. Limburg’s valuable mix of cancer prevention experience in both the clinical and scientific research arenas will provide a great advantage to our company. He’ll also guide the expansion of our relationships with key opinion leaders and institutions in the cancer community.”

While at Mayo Clinic, Dr. Limburg has served as medical director of Mayo Clinic Global Business Solutions (GBS), which delivers products and services that extend Mayo Clinic’s specialized clinical knowledge and expertise worldwide. Dr. Limburg also served as medical director of several of Mayo Clinic’s health and well-being programs.

Dr. Limburg’s extensive research and clinical experience with gastrointestinal cancer makes him well suited to advise Exact Sciences where he will assess research opportunities to inform, expand and accelerate the adoption of effective colon cancer screening options such as Cologuard. He will continue to serve as a gastroenterologist with Mayo Clinic’s Division of Gastroenterology and Hepatology, co-leader of the Cancer Prevention and Control program within Mayo Clinic Cancer Center, and principal investigator for the NCI-funded cancer prevention network clinical trials consortium. He is a medical advisory board member of Fight Colorectal Cancer, a patient education and advocacy group.

“I am excited to join the outstanding team at Exact Sciences that is already making extraordinary progress toward its mission of fighting colon cancer through early detection,” Dr. Limburg said. “Colorectal cancer is highly preventable with proper screening, yet millions of adult Americans are not being screened as recommended. As a result, colon cancer has remained the second leading cancer killer in the U.S. The company’s Cologuard colon cancer screening test was developed in collaboration with Mayo Clinic and has built a strong reputation in both the patient and healthcare provider communities because of its simplicity, accuracy and effectiveness. I look forward to working with the team at Exact Sciences to continue to expand the adoption of Cologuard and to offer guidance in building out the company’s cancer detection test portfolio.”

Dr. Limburg earned a Bachelor of Arts in chemistry from Augustana College, a Doctor of Medicine from Mayo Medical School, and Master of Public Health from the Johns Hopkins School of Hygiene and Public Health. He completed his internal medicine residency and gastroenterology and hepatology fellowship training at the Mayo Graduate School of Medicine. Dr. Limburg also completed an advanced fellowship in preventive oncology at the National Cancer Institute.

Mayo Clinic and Dr. Limburg have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

About Cologuard
Cologuard was approved by the FDA in August 2014 and results from Exact Sciences’ prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the American Cancer Society’s (2014) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2016) and National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit Rx Only.

About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. For more information, please visit the company’s website at, follow Exact Sciences on Twitter @ExactSciences or find Exact Sciences on Facebook.

Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payer reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

J.P. Fielder
Exact Sciences Corp.

View original content with multimedia: